MX2016011674A - Combinacion que comprende un inhibidor de btk y un inhibidor de akt. - Google Patents
Combinacion que comprende un inhibidor de btk y un inhibidor de akt.Info
- Publication number
- MX2016011674A MX2016011674A MX2016011674A MX2016011674A MX2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- akt
- btk
- combination
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinación novedosa que comprende un inhibidor de BTK, por ejemplo 1-[(3R)-3-[4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pir imidin-1-il] piperidin-1-il]prop-2-en-1-ona, o una sal farmacéuticamente aceptable del mismo, y un inhibidor de AKT, por ejemplo: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-( 4-cloro-1-metil-1H-pirazol-5-il)-2-tiofencarboxamida, o una sal farmacéuticamente aceptable del mismo, y agentes antineoplásicos adicionales opcionales; composiciones farmacéuticas que comprenden los mismos y métodos de uso de tales combinaciones en el tratamiento de condiciones en las que la inhibición de BTK y/o AKT es beneficiosa, por ejemplo, cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951640P | 2014-03-12 | 2014-03-12 | |
| PCT/IB2015/051380 WO2015136398A1 (en) | 2014-03-12 | 2015-02-24 | Combination comprising a btk inhibitor and an akt inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011674A true MX2016011674A (es) | 2017-04-27 |
Family
ID=52630445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011674A MX2016011674A (es) | 2014-03-12 | 2015-02-24 | Combinacion que comprende un inhibidor de btk y un inhibidor de akt. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170020878A1 (es) |
| EP (1) | EP3116546A1 (es) |
| JP (1) | JP2017507963A (es) |
| KR (1) | KR20160127754A (es) |
| CN (1) | CN106456642A (es) |
| AU (1) | AU2015228475B9 (es) |
| CA (1) | CA2942204A1 (es) |
| MX (1) | MX2016011674A (es) |
| RU (1) | RU2016139697A (es) |
| WO (1) | WO2015136398A1 (es) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| JP2012516344A (ja) | 2009-01-30 | 2012-07-19 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 結晶質ｎ−｛（１ｓ）−２−アミノ−１−［（３−フルオロフェニル）メチル］エチル｝−５−クロロ−４−（４−クロロ−１−メチル−１ｈ−ピラゾール−５−イル）−２−チオフェンカルボキサミド塩酸塩 |
| SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| JP5859640B2 (ja) | 2011-05-17 | 2016-02-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼ阻害剤 |
| SG10201801668WA (en) | 2011-06-10 | 2018-03-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| JP2014522860A (ja) | 2011-07-19 | 2014-09-08 | メルク・シャープ・アンド・ドーム・ベー・フェー | Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
| WO2013067260A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Bicyclic piperazine compounds |
| LT2786996T (lt) | 2011-11-29 | 2017-01-10 | Ono Pharmaceutical Co., Ltd. | Purinono darinio hidrochloridas |
| CN104169260A (zh) | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | 新三嗪衍生物 |
| WO2013161848A1 (ja) | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規１，２，４－トリアジン誘導体 |
| SG11201408067YA (en) * | 2012-06-04 | 2015-01-29 | Pharmacyclics Inc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| MX368112B (es) | 2012-06-18 | 2019-09-18 | Principia Biopharma Inc | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. |
-
2015
- 2015-02-24 EP EP15708605.9A patent/EP3116546A1/en not_active Withdrawn
- 2015-02-24 CA CA2942204A patent/CA2942204A1/en not_active Abandoned
- 2015-02-24 MX MX2016011674A patent/MX2016011674A/es unknown
- 2015-02-24 US US15/124,301 patent/US20170020878A1/en not_active Abandoned
- 2015-02-24 RU RU2016139697A patent/RU2016139697A/ru not_active Application Discontinuation
- 2015-02-24 KR KR1020167024720A patent/KR20160127754A/ko unknown
- 2015-02-24 WO PCT/IB2015/051380 patent/WO2015136398A1/en active Application Filing
- 2015-02-24 JP JP2016556821A patent/JP2017507963A/ja active Pending
- 2015-02-24 AU AU2015228475A patent/AU2015228475B9/en not_active Ceased
- 2015-02-24 CN CN201580013442.2A patent/CN106456642A/zh active Pending
-
2018
- 2018-06-18 US US16/010,945 patent/US20190151319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190151319A1 (en) | 2019-05-23 |
| EP3116546A1 (en) | 2017-01-18 |
| AU2015228475A1 (en) | 2016-09-01 |
| WO2015136398A1 (en) | 2015-09-17 |
| CA2942204A1 (en) | 2015-09-17 |
| RU2016139697A (ru) | 2018-04-12 |
| KR20160127754A (ko) | 2016-11-04 |
| CN106456642A (zh) | 2017-02-22 |
| RU2016139697A3 (es) | 2018-10-19 |
| AU2015228475B2 (en) | 2017-08-17 |
| AU2015228475B9 (en) | 2017-09-21 |
| US20170020878A1 (en) | 2017-01-26 |
| JP2017507963A (ja) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| MX2016010754A (es) | Sales y forma solida de un inhibidor btk. | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
| MX2015008196A (es) | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| NZ724250A (en) | Human plasma kallikrein inhibitors | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
| WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process |